PRKCD: Protein kinase C delta type
Calcium-independent, phospholipid- and diacylglycerol (DAG)- dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti- apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PRKCD, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Delcasertib | Phase 2 | Kai Pharmaceuticals | Other | InhibitorProtein kinase C delta inhibitor | 0 |
- Autoimmune lymphoproliferative syndrome0.69
- Acute myeloid leukemia0.56
- Mast cell leukemia0.47
- Systemic mastocytosis0.47
- Mastocytosis0.46
- Neoplasm0.41
- Systemic lupus erythematosus0.39
- Acute myeloid leukemia by FAB classification0.37
- Non-Hodgkin lymphoma0.37
- Adolescent idiopathic scoliosis0.34
- Myelodysplastic syndrome0.33
- Otosclerosis0.29
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2996, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q05655, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets